论文部分内容阅读
目的探讨雷米普利对高血压病患者胰岛素抵抗、血浆内皮素与降钙素基因相关肽变化的影响。方法共纳入120例高血压病患者,平均分为两组,A组给予雷米普利治疗,B组给予硝苯地平治疗。所有研究对象均于治疗前后检测空腹血糖,空腹胰岛素,血浆内皮素(ET)及降钙素基因相关肽(CGRP)水平。结果 A组(雷米普利组)明显优于B组(硝苯地平组),总有效率分别为86.7%及76.7%,差异有统计学意义(P﹤0.05);治疗后两组患者的IRI、ET、CGRP均有明显改善,差异有统计学意义(P﹤0.05);与B组相比,A组患者在治疗后IRI、ET、CGRP改善效果更明显,差异有统计学意义(P﹤0.05)。结论雷米普利可以有效降低高血压病患者的血压水平,且治疗后IRI、ET、CGRP均有明显改善,值得临床推广应用。对高血压病患者进行早期雷米普利干预是必要的。
Objective To investigate the effects of ramipril on the changes of insulin resistance, plasma endothelin and calcitonin gene-related peptide in patients with essential hypertension. Methods A total of 120 patients with hypertension were enrolled. The patients were divided equally into two groups. Group A received ramipril and group B received nifedipine. Fasting blood glucose, fasting insulin, plasma endothelin (ET) and calcitonin gene related peptide (CGRP) were measured in all the subjects before and after treatment. Results The total effective rate in group A (ramipril group) was significantly higher than that in group B (nifedipine group), the total effective rates were 86.7% and 76.7%, respectively, with statistical significance (P <0.05). After treatment, (P <0.05). Compared with group B, the improvement effect of IRI, ET and CGRP in group A was more obvious after treatment, and the difference was statistically significant (P <0.05). Conclusion Ramipril can effectively reduce the blood pressure in patients with hypertension, and after treatment IRI, ET, CGRP were significantly improved, worthy of clinical application. Early intervention with ramipril in hypertensive patients is necessary.